Molecular Therapy in Myotonic Dystrophy: Focus on RNA Gain-of-function
Overview
Molecular Biology
Affiliations
Myotonic dystrophy (DM) is a complex, dominantly inherited, multisystem disorder and the archetypal example of an RNA gain-of-function disease. Unstable expansions of (CTG*CAG)n or (CCTG*CAGG)n repeat tracts in the DMPK and ZNF9 genes cause the two known subtypes of myotonic dystrophy, DM1 and DM2, for which no cure or effective molecular treatment exists. Focus in therapeutic development is currently on toxic, expanded (C/CUG)n RNAs. A series of recent papers provide proof of concept of promising strategies using antisense oligonucleotides or small organic compounds aimed at either complete elimination of expanded (CUG)n RNA transcripts or prevention of detrimental protein binding to thermodynamically stable (C/CUG)n hairpin structures. These developments offer new hope to patients with DM, even though several hurdles still have to be overcome before they can be introduced into clinical practice.
El Boujnouni N, van der Bent M, Willemse M, t Hoen P, Brock R, Wansink D Mol Ther Nucleic Acids. 2023; 32:622-636.
PMID: 37200862 PMC: 10185704. DOI: 10.1016/j.omtn.2023.04.010.
Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1.
Liu J, Guo Z, Yan X, Yang Y, Huang S Front Aging Neurosci. 2021; 13:755392.
PMID: 34867280 PMC: 8634727. DOI: 10.3389/fnagi.2021.755392.
Ausems C, Raaijmakers R, van den Broek W, Willemse M, van Engelen B, Wansink D Mol Ther Methods Clin Dev. 2019; 15:120-132.
PMID: 31649961 PMC: 6804802. DOI: 10.1016/j.omtm.2019.09.002.
Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI.
Heskamp L, van Nimwegen M, Ploegmakers M, Bassez G, Deux J, Cumming S Neurology. 2019; 92(24):e2803-e2814.
PMID: 31118244 PMC: 6598795. DOI: 10.1212/WNL.0000000000007648.
Dastidar S, Ardui S, Singh K, Majumdar D, Nair N, Fu Y Nucleic Acids Res. 2018; 46(16):8275-8298.
PMID: 29947794 PMC: 6144820. DOI: 10.1093/nar/gky548.